Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John F Seymour, Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John F Seymour

Abstract

Purpose: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non-Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(FL), 17%, n = 5/29], and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts.

Patients and methods: All patients (n = 106) received venetoclax monotherapy in dose cohorts of 200 to 1,200 mg daily until disease progression or unacceptable toxicity. ORR, progression-free survival (PFS), duration of response (DoR), and adverse events (AEs) were evaluated.

Results: At a median follow-up of 38.5 months (range, 30.0-46.5), the median PFS for all 106 patients was 5.4 [95% confidence interval (CI), 3.5-8.4] months (FL, 10.8; MCL, 11.3; MZL, 21.2; and WM, 30.4). The median DoR was 14.9 (95% CI, 9.7-27.6) months (FL, 26.6; MCL, 15.7; MZL, 20.1; and WM, 25.3). Achievement of CR versus PR predicted longer DoR in both MCL (31.5 vs. 10.1 months) and FL (37.6 vs. 9.7 months). All grade hematologic AEs were infrequent: neutropenia (19%), anemia (19%), and thrombocytopenia (17%), with no new cytopenias after 2 years on therapy. Nonhematologic AEs included nausea (49%), diarrhea (46%), fatigue (44%), with decreased incidence after 1 year.

Conclusions: Venetoclax monotherapy has a manageable safety profile and achieves durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieve CR. Further research is warranted on combination strategies to enhance the durability of response to venetoclax.

Trial registration: ClinicalTrials.gov NCT01328626.

©2021 The Authors; Published by the American Association for Cancer Research.

Figures

Figure 1.
Figure 1.
Swimmer plot describing overall response and DoR in patients. CR, complete remission; PR, partial remission; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; WM, Waldenström macroglobulinemia. Patients were censored at their last disease assessment if they did not have confirmed disease progression. Rituximab was administered to patients at doses of 375 mg/m2.
Figure 2.
Figure 2.
Kaplan–Meier curves duration of response (A) PFS (B) in patients with MCL and FL.

References

    1. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013;23:139–41.
    1. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. . BCL2 expression is a prognostic marker for the activated B-cell–like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961–8.
    1. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012;30:3127–35.
    1. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. . Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 2018;24:3967–80.
    1. Choe H, Ruan J. Next generation of targeted molecules for non-Hodgkin lymphomas: small-molecule inhibitors of intracellular targets and signaling pathways. Oncology 2016;30:847–58.
    1. Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al. . B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res 2017;23:4212–23.
    1. VENCLEXTA. Prescribing information. North Chicago, IL: AbbVie Inc.; South San Francisco, CA: Genentech USA Inc; 2020. Available from: .
    1. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. . Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol 2017;35:826–33.
    1. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. . International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017;28:1436–47.
    1. Handunnetti S, Anderson MA, Roberts AW, Davids MS, Ma S, Boyer M, et al. . Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. eJHaem 2021;2:266–71.
    1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
    1. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. . Update on treatment recommendations from The Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120–6.
    1. Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. . Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res 2018;24:4371–9.
    1. Castillo JJ, Gustine J, Meid K, Dubeau T, Keezer A, Allan JN, et al. . Multicenter prospective phase II study of venetoclax in patients with previously treated waldenstrom macroglobulinemia. Blood 2018;132:2888.
    1. Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, et al. . Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. Br J Haematol 2019;186:e188–e91.
    1. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. . Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378:1211–23.
    1. Handunnetti SM, Khot A, Anderson MA, Blombery P, Burbury K, Ritchie D, et al. . Safety and efficacy of ibrutinib in combination with venetoclax in patients with marginal zone lymphoma: preliminary results from an open label, phase II study. Blood 2019;134:3999.
    1. de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. . Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol 2018;29:1932–8.
    1. Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. . Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood 2021;137:877–87.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren